Infermedica, a Poland-based health diagnostics system provider that counts media company Müller Medien as an investor, has received $10.3m in series A funding.
Heal Capital co-led the round with the European Bank for Reconstruction and Development (EBRD) and it also featured Karma Ventures, Inovo Venture Partners and Dreamit Ventures.
Founded in 2012, Infermedica had created an online platform that uses artificial intelligence to check patients’ symptoms and make preliminary diagnoses of diseases. It also provides information to help call centre staff instruct patients in triage for illnesses or injuries.
The series A funds will be used for research and development, as the company looks to improve the platform’s functionality in symptom checking and decision analysis, and to drive international growth in the US and Germany.
Infermedica had previously secured $3.7m in a June 2019 seed round led by Karma Ventures that included Müller Medien, Inovo Venture Partners and Dreamit Ventures.
Piotr Orzechowski, Infermedica’s chief executive, said: “We are thrilled to welcome EBRD and Heal Capital as new investors on board of our venture. Our mission is to improve quality and access to primary care with the use of AI-powered, constantly improving technology.
“As we all know, the Covid-19 pandemic has placed great pressure on health systems globally and it’s our obligation to help healthcare providers deliver safe and timely care.”
